Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 6, 2015

Primary Completion Date

January 14, 2020

Study Completion Date

January 14, 2020

Conditions
Metastatic Prostate CarcinomaMetastatic Prostatic AdenocarcinomaProstate Carcinoma Metastatic to the Bone
Interventions
PROCEDURE

Robotic Assisted Radical Prostatectomy

Undergo RARP

PROCEDURE

Conventional open retropubic radical prostectomy

Undergo conventional open RRP

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)

LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)

Trial Locations (3)

91010

City of Hope National Medical Center (COH), Duarte

92868

University of California, Irvine (UCI), Orange

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rutgers Cancer Institute of New Jersey

OTHER

lead

Rutgers, The State University of New Jersey

OTHER

NCT02458716 - Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter